Jan. 14 at 8:43 PM
$HELP Following the transition to Helus Pharma, the company updated the internal naming of its clinical programs from CYB003 and CYB004 to HLP003 and HLP004. This change reflects corporate alignment after the rebrand and does not alter the underlying compounds, mechanisms of action, or clinical development plans.
Information regarding molecular origin, pharmacology, and development rationale continues to be disclosed through regulatory filings, investor materials, and clinical trial registries. As programs advance, communication increasingly follows the conventions used in later stage clinical and regulatory settings.
Helus Pharma’s pipeline updates are intended to emphasize validated data, trial progress, and regulatory milestones, with terminology aligned to clinical precision and consistency.
We welcome questions from the investor community and remain committed to clear, transparent communication as programs progress.
